Editing Digoxin (section)

==Overdose==
In overdose, the usual supportive measures are needed. If [[arrhythmias]] prove troublesome, or malignant [[hyperkalemia]] occurs (inexorably rising [[potassium]] level due to paralysis of the cell membrane-bound, [[ATPase]]-dependent Na/K pumps), the specific [[antidote]] is antidigoxin (antibody fragments against digoxin, trade names Digibind and Digifab).<ref name=Flanagan2004>{{cite journal | vauthors = Flanagan RJ, Jones AL | title = Fab antibody fragments: some applications in clinical toxicology | journal = Drug Safety | volume = 27 | issue = 14 | pages = 1115–33 | year = 2004 | pmid = 15554746 | doi = 10.2165/00002018-200427140-00004 | url = http://drugsafety.adisonline.com/pt/re/drs/fulltext.00002018-200427140-00004.htm | archive-url = https://archive.today/20130116063055/http://drugsafety.adisonline.com/pt/re/drs/fulltext.00002018-200427140-00004.htm | url-status = dead | archive-date = January 16, 2013 | s2cid = 40869324 | access-date = July 16, 2007 | url-access = subscription }}</ref> The mechanism of action for drugs such as Digibind and Digifab, used when adverse events occur with the use of digoxin, is that the FAB regions on the antibodies created against digoxin expedite the excretion of the drug into urine. Therefore, the amount of digoxin in the body decreases quickly as it gets excreted rapidly.